A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
NCT00429260
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
125
Enrollment
INDUSTRY
Sponsor class
Conditions
Depressive Disorder
Interventions
DRUG:
Saredutant
Sponsor
Sanofi